BLUE

bluebird bio
BLUE

Overview Fund Activity
Delisted

BLUE was delisted on the 30th of May, 2025.

Back to rankings

210 hedge funds and large institutions have $3.8B invested in bluebird bio in 2015 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
210
Holders Change
+41
Holders Change %
+24.26%
% of All Funds
5.6%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.11%
New
59
Increased
71
Reduced
68
Closed
18
Calls
$97.3M
Puts
$70M
Net Calls
+$27.3M
Net Calls Change
-$1.56M

Top Buyers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
$155M
2
Vanguard Group
Vanguard Group
Pennsylvania
$167M
3
O
OrbiMed
New York
$66.5M
4
Capital World Investors
Capital World Investors
California
$164M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
$232M

Top Sellers

1
TRV
Third Rock Ventures
Massachusetts
$0
2
RCM
RA Capital Management
Massachusetts
$24.2M
3
FCM
Frontier Capital Management
Massachusetts
$30.2M
4
DM
Deerfield Management
New York
$76.2M
5
PHS
PFM Health Sciences
California
$24.1M
Name Holding Trade Value Shares
Change 		Shares
Change %
MFS
226
MSI Financial Services
Massachusetts
– -$73K -61 Closed
QT
227
Quantbot Technologies
New York
– -$56K -47 Closed
Credit Agricole
228
Credit Agricole
France
– -$19K -15 Closed
6 7 8 9
10